Bioventus Inc.
BVSNasdaq
$12.06
↓ -3.0%Jul 17 close · end-of-day
Price
1Y↑ +81.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$844.3M
Enterprise Value
$1.1B
P/E
29.4
P/S
1.5
P/B
4.5
EV/EBITDA
10.4
PEG
—
FCF Yield
11.9%
Dividend Yield
—
Revenue (TTM)
$576.3M
Net Income (TTM)
$28.5M
Free Cash Flow (TTM)
$100.6M
Gross Margin
68.7%
Operating Margin
10.0%
Net Margin
4.9%
ROE
15.1%
ROIC
13.5%
Debt / Equity
1.4
Net Cash
-$236.2M
Return 1Y
+85.8%
Company profile
Bioventus Inc. focuses on developing and commercializing treatments that engage and enhance the body's natural healing process. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries. Restorative therapies comprise an ultrasonic bone healing system for fracture care.
- CEO
- Kenneth M. Reali
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 1,200
- Headquarters
- North Carolina
- Website
- bioventus.com
Management & directors
- Church Katrina JSVP & Chief Compliance Officer
- D'Adamio AnthonySVP & General Counsel
- Singleton Mark LeonardSVP & CFO
- Claypoole Robert EPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
BVS Q1 2026 Earnings
Period ends 2026-03-28
MetricActualYoY
Revenue$132.1M↑ +6.6%
Diluted EPS$0.04↓ -200.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $321.2M | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Gross profit | $233.5M | $302.7M | $331.1M | $328.2M | $388.2M | $388.2M |
| Operating income | $21.2M | $12.1M | -$167.2M | -$81.7M | -$15.2M | $54.0M |
| Net income | $16.4M | $19.4M | -$158.7M | -$156.2M | -$36.1M | $22.7M |
| Diluted EPS | — | -$0.15 | -$2.59 | -$2.49 | -$0.56 | $0.33 |
| Operating cash flow | $71.8M | $23.0M | -$13.5M | $15.3M | $38.8M | $74.7M |
| Free cash flow | $55.2M | $9.5M | -$15.0M | $8.0M | $37.8M | $72.1M |
| Gross margin | 72.7% | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% |
| Operating margin | 6.6% | 2.8% | -32.7% | -16.0% | -2.7% | 9.5% |
| Net margin | 5.1% | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.2M | $139.0M | $153.6M | $123.9M | $147.7M | $138.7M | $157.9M | $132.1M |
| Gross profit | $103.6M | $93.6M | $102.7M | $83.1M | $102.1M | $94.2M | $108.8M | $90.8M |
| Operating income | -$31.5M | $3.6M | $7.7M | $4.9M | $18.4M | $11.3M | $19.5M | $8.4M |
| Net income | -$25.7M | -$5.2M | -$388,000.00 | -$2.6M | $7.5M | $3.2M | $14.8M | $3.1M |
| Diluted EPS | -$0.40 | -$0.08 | $0.00 | -$0.04 | $0.11 | $0.05 | $0.21 | $0.04 |
| Operating cash flow | $15.2M | $10.3M | $19.3M | -$19.3M | $25.9M | $30.1M | $38.0M | $8.9M |
| Free cash flow | $15.1M | $10.3M | $18.7M | -$20.2M | $25.3M | $29.6M | $37.4M | $8.4M |
| Gross margin | 68.5% | 67.3% | 66.8% | 67.0% | 69.1% | 68.0% | 68.9% | 68.7% |
| Operating margin | -20.8% | 2.6% | 5.0% | 3.9% | 12.4% | 8.1% | 12.3% | 6.4% |
| Net margin | -17.0% | -3.7% | -0.3% | -2.1% | 5.1% | 2.3% | 9.3% | 2.4% |
Company news
Jul 10, 2026
Jul 8, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Bartholdson John A. | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | SUTTER MARTIN P | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | STALNECKER SUSAN M | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | NOHRA GUY P | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | NEELS GUIDO J | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | McMurry-Heath Michelle | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | Ladone Mary Kay | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | HAWKINS WILLIAM A | Option exercise | 39,789 | $0.00 | $0.00 | filing |
| 2026-06-02 | Cowdy Philip G. | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-06-02 | Beyer Pat | Option exercise | 32,282 | $0.00 | $0.00 | filing |
| 2026-04-10 | Singleton Mark Leonard· SVP & CFO | Tax withholding | 5,648 | $9.06 | $51,170.88 | filing |
| 2026-04-10 | D'Adamio Anthony· SVP & General Counsel | Tax withholding | 4,312 | $9.06 | $39,066.72 | filing |
| 2026-04-10 | CHURCH KATRINA J· SVP & Chief Compliance Officer | Tax withholding | 1,868 | $9.06 | $16,924.08 | filing |
| 2026-04-10 | CHURCH KATRINA J· SVP & Chief Compliance Officer | Option exercise | 4,300 | $0.00 | $0.00 | filing |
| 2026-04-10 | D'Adamio Anthony· SVP & General Counsel | Option exercise | 9,925 | $0.00 | $0.00 | filing |
| 2026-04-10 | Singleton Mark Leonard· SVP & CFO | Option exercise | 13,000 | $0.00 | $0.00 | filing |
| 2026-03-20 | Singleton Mark Leonard· SVP & CFO | Tax withholding | 8,091 | $8.64 | $69,906.24 | filing |
| 2026-03-20 | Singleton Mark Leonard· SVP & CFO | Option exercise | 18,625 | $0.00 | $0.00 | filing |
| 2026-03-11 | McMurry-Heath Michelle | Sale | 12,000 | $8.79 | $105,439.20 | filing |
| 2026-02-15 | Singleton Mark Leonard· SVP & CFO | Tax withholding | 9,429 | $8.27 | $77,977.83 | filing |
| 2026-02-15 | D'Adamio Anthony· SVP & General Counsel | Tax withholding | 6,327 | $8.27 | $52,324.29 | filing |
| 2026-02-15 | CHURCH KATRINA J· SVP & Chief Compliance Officer | Tax withholding | 2,133 | $8.27 | $17,639.91 | filing |
| 2026-02-15 | Singleton Mark Leonard· SVP & CFO | Option exercise | 20,153 | $0.00 | $0.00 | filing |
| 2026-02-15 | D'Adamio Anthony· SVP & General Counsel | Option exercise | 12,980 | $0.00 | $0.00 | filing |
| 2026-02-15 | CHURCH KATRINA J· SVP & Chief Compliance Officer | Option exercise | 4,375 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.